Table 1 Demographic and clinical characteristics of the study cohort
Parameters | Seronegative Control (n = 63) | Seropositive Patients (n = 383) | P-value | ||||
|---|---|---|---|---|---|---|---|
Healthy (n = 50) | Interferent (n = 13) | Non-Viremic (n = 193) | Viremic (n = 190) | ||||
HBV+ (n = 5) | HBV+/CRF (n = 8) | Interferents | |||||
CRF (n = 5, 2.6%) | DM (n = 2, 1.05%) | ||||||
DM (n = 5, 2.6%) | |||||||
Gender (n, %) | |||||||
 Male | 29 (58%) | 3 (60%) | 6 (75%) | 95 (49.22%) | 128 (67.37%) |  > 0.05 | |
 Female | 21 (42%) | 2 (40%) | 2 (25%) | 98 (50.78%) | 62 (32.63%) | ||
 Age (Yrs) | 43.5 ± 8.56 | 50.8 ± 4.63 | 59.2 ± 5.5 | 45.24 ± 6.24 | 52 ± 9.3 |  > 0.05 | |
 ≤ 50, n (%) | 21(42%) | 2 (40%) | - | 83 (43%) | 90 (47.37%) |  | |
 > 50, n (%) | 29 (58%) | 3 (60%) | 8 (100%) | 110 (57%) | 100 (52.63%) |  | |
HCV-Ab | Negative | Positive | Â | ||||
Log10 HCV-RNA (IU/mL) | - | - | 5.785 ± 0.84 |  | |||
 ≤ 8 × 105, n (%) |  | 102 (29.91%) |  | ||||
 > 8 × 105, n (%) |  | 88 (28.8%) |  | ||||
Subtype | |||||||
 4a/m/o (n, %) | - | - | 152 (80%)/ 10 (5.26%)/ 28 (14.73%) |  | |||
 ALT (U/L) | 25.27 ± 10.18 | 38 ± 5.08 | 45.54 ± 7.2 | 28.34 ± 8.93 | 41.59 ± 23.12 |  < 0.0001 | |
 AST(U/L) | 26.74 ± 7.27 | 35.88 ± 6.12 | 26.74 ± 6.3 | 25.45 ± 7.76 | 36.12 ± 19.38 |  < 0.0001 | |
 Total BiL (mg/dL) | 0.624 ± 0.1 | 0.824 ± 0.21 | 1.24 ± 0.32 | 0.722 ± 0.27 | 0.764 ± 0.26 | 0.003 | |
S/Co value | Denatured antigens | - | 1.22 ± 0.39 | 2.702 ± 0.79 |  < 0.0001 | ||
Soluble antigens | 1.884 ± 0.66 | 3.753 ± 1.02 | |||||